共进股份(603118) - 2018 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 99.03% to CNY 975,068.64, primarily due to a decline in sales and increased material costs[8] - Revenue for the period was CNY 1,685,102,009.08, representing an 8.77% decrease compared to the same period last year[6] - Basic earnings per share dropped by 99.00% to CNY 0.0013, reflecting the significant decline in net profit[6] - The weighted average return on equity decreased by 2.30 percentage points to 0.02%[6] - Other income decreased by 84.45% to ¥3,352,632.79, mainly due to reduced government subsidies recognized in the current period[16] - Net profit for Q1 2018 was ¥1,114,900.07, a significant decline from ¥100,224,027.45 in Q1 2017, representing a decrease of 98.9%[27] - The company recorded a comprehensive income total of ¥465,332.66 for Q1 2018, compared to ¥100,181,842.96 in the same period last year, a decline of 99.5%[28] - The net profit for Q1 2018 was a loss of ¥23,891,934.96, compared to a profit of ¥101,240,922.34 in the same period last year[30] Cash Flow and Liquidity - Operating cash flow increased by 33.10% to CNY 159,328,373.28, driven by higher customer bill collections and increased export tax refunds[8] - Net cash flow from operating activities increased by 33.10% to ¥159,328,373.28 compared to ¥119,703,466.14 in the previous year[17] - Total cash inflow from operating activities was ¥1,997,938,281.47, up from ¥1,584,517,469.87 year-over-year[32] - Cash outflow from operating activities totaled ¥1,838,609,908.19, compared to ¥1,464,814,003.73 in the previous year[32] - The ending cash and cash equivalents balance was ¥544,805,659.81, down from ¥579,749,251.60 at the end of Q1 2017[33] Assets and Liabilities - Total assets decreased by 1.58% to CNY 7,111,929,174.08 compared to the end of the previous year[6] - Cash and cash equivalents decreased by 33.04% to ¥549,172,871.13 due to increased repayment of bank loans and interbank transactions[15] - Accounts receivable decreased by 44.91% to ¥484,063,345.04 primarily due to increased bill collection and endorsements[15] - Total current assets decreased from ¥5,271,911,820.25 to ¥5,002,115,139.69, a decline of approximately 5.12%[19] - Total liabilities decreased from ¥2,880,223,531.65 to ¥2,721,141,477.07, a reduction of approximately 5.52%[21] - The company's total assets decreased to ¥7,018,410,158.50 from ¥7,257,377,044.09, reflecting a decline of 3.3%[25] - Total liabilities decreased to ¥2,810,378,736.10 from ¥3,026,348,686.73, a reduction of 7.1%[25] - The company's equity totaled ¥4,208,031,422.40, slightly down from ¥4,231,028,357.36, indicating a decrease of 0.5%[25] Expenses and Costs - Operating costs decreased by 6.46% to ¥1,499,397,649.44, reflecting cost management efforts[16] - The company reported a significant increase in financial expenses, rising to ¥15,055,863.58 from a negative ¥3,306,652.84 in the previous year[27] - The company’s financial expenses surged by 555.32% to ¥15,055,863.58, primarily due to increased exchange losses[16] - Research and development expenses increased compared to the same period last year, contributing to the decline in net profit[8] Shareholder Information - The total number of shareholders reached 46,597, indicating a broad base of investor interest[12] - The net profit attributable to minority shareholders increased by 2459.34% to ¥45,744,358.50, driven by the acquisition of Jiangsu Suhang[16] Inventory and Prepayments - The company’s inventory increased by 13.11% to ¥890,024,289.79, indicating a buildup of stock[15] - Prepayments increased by 84.31% to ¥56,976,254.56, mainly due to prepayment for equity repurchase and procurement of medical products[15] Investment Activities - The company reported a net cash outflow from investing activities of ¥183,531,433.92, compared to a net inflow of ¥187,725,657.98 in the previous year[17] - Cash flow from investing activities showed a net outflow of ¥183,531,433.92, a decrease from a net inflow of ¥187,725,657.98 in Q1 2017[32] Sales Performance - The company reported a significant increase in sales revenue from ¥1,421,940,828.94 to ¥1,837,894,334.36, reflecting a growth of approximately 29.3% year-over-year[31]